Menlo Park, CA, June 11, 2019 --(PR.com
)-- Life Science Strategy Group (LSSG), a leading strategic consulting firm to the CRO industry, is pleased to announce the availability of its 2019 syndicated report on Real-World Evidence – "A Market at an Inflection Point and its Impact on the CRO Industry." This benchmark study provides a detailed look into the pharmaceutical industry’s utilization of real-world evidence (RWE), the changing RWD/RWE landscape within biopharmaceutical companies and its implications on CRO business models and strategies.
Life Science Strategy Group's new report provides insights from 100 professionals from small, medium, and large global biopharmaceutical companies into the current attitudes towards RWE, its role in the product lifecycle, the current state of RWE-based strategy implementation and outsourcing and perceptions of leading CRO providers including IQVIA, Covance, Parexel, PPD and ICON. Further, the report discusses the implications of the biopharmaceutical industry’s adoption of RWE-based approaches on traditional CROs.
The report provides data on RWE trends, use and study design, barriers to RWE use to support product development, RWD/RWE buying processes, vendor selection criteria, and RWE outsourcing. According to Jon Meyer, Principal, Life Science Strategy Group, “Biopharmaceutical companies are increasing their investment in real-world data, analytics and evidence with mixed results. Traditional CROs are working actively to augment internal capabilities with RWE-based services. However, given the challenges involved and 'one-off' nature of real-world evidence generation, the CRO industry is at a crossroads.”
To learn more about the rapidly changing RWE marketplace and its impact on CROs, or to download sample pages from the report, visit http://lifesciencestrategy.com/publications/cro-industry/pubs-cro-real-world-june-2019/
About Life Science Strategy Group, LLC
Life Science Strategy Group, LLC is a consultancy specializing in strategic consulting, market research engagements and syndicated publications across a variety of therapeutic, technology and service industries including contract research services, pharmaceutical, biotechnology, medical devices, diagnostics and drug discovery.